新型冠狀病毒

Two Covid-19 drug trials halted on safety concerns

Johnson & Johnson and Eli Lilly announce pauses in blow to hopes for pandemic remedy

Safety concerns prompted two big US pharmaceutical companies to halt trials of experimental Covid-19 drugs, dealing a blow to hopes for a medical intervention to stop the pandemic.

Eli Lilly said on Tuesday it was halting enrolment for its antibody treatment, similar to one taken by US President Donald Trump this month. Johnson & Johnson said it was pausing all trials of its experimental Covid-19 vaccine after one participant developed an “adverse reaction”.

J&J said it was not immediately clear what caused the reaction in the participant, or whether it was linked to the vaccine. Neither company would give further details of what the safety concerns were.

您已閱讀25%(661字),剩餘75%(1996字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×